Impact of bundle care on quality of life and nutrition after transarterial chemoembolization

Table 1 Baseline and disease-related data of the two groups before nursing care, n (%)

Variable	Grouping	Subjects of study (n = 80)	Control group (n = 40)	Test group (n = 40)	χ2/Z/t	P value
Age, mean ± SD		60.95 ± 8.22	59.97 ± 8.21	61.93 ± 8.19	0.134	0.863
Sex	Male	67 (83.75)	34 (85.00)	33 (82.50)	0.092	0.762
	Female	13 (16.25)	6 (15.00)	7 (17.50)
BMI, mean ± SD		21.57 ± 2.91	21.68 ± 2.58	21.47 ± 3.26	0.365	0.684
Smoking history	No	26 (32.5)	10 (25.0)	16 (40.0)	2.051	0.152
	Yes	54 (67.5)	30 (75.0)	24 (60.0)
Drinking history	No	27 (33.75)	11(27.50)	16 (40.0)	1.398	0.237
	Yes	53 (66.25)	29 (72.50)	24 (60.0)
CCI grouping	0	69 (86.25)	36 (90.0)	33 (82.5)	4.273	0.118
	1	4 (5.0)	0 (0.0)	4 (10.0)
	2	7 (8.75)	4 (10.0)	3 (7.5)
	≥ 3	0 (0.0)	0 (0.0)	0 (0.0)
Hepatitis history	No	6 (7.5)	1 (2.5)	5 (12.5)	3.394	0.335
	Hepatitis B	66 (82.5)	34 (85.0)	32 (80.0)
	Hepatitis C	6 (7.5)	4 (10.0)	2 (5.0)
	Other	2 (2.5)	1 (2.5)	1 (2.5)
Child-Pugh class	A	70 (87.5)	34 (85.0)	36 (90.0)	0.457	0.499
	B	10 (12.5)	6 (15.0)	4 (10.0)
TACE times	-	2.00 (1.00-4.00)	2.50 (1.00-4.00)	2.00 (1.00-4.75)	0.832	0.423
	1-2	42 (52.5)	20 (50.0)	22 (55.0)	0.223	0.894
	3-5	27 (33.75)	14 (35.0)	13 (32.5)	-	-
	> 5	11 (13.75)	6 (15.0)	5 (12.5)	-	-
TACE embolization type	cTACE	61 (76.25)	29 (72.5)	32 (80.0)	0.621	0.431
	DEB-TACE	19 (23.75)	11 (27.5)	8 (20.0)

BMI: Body mass index; CCI: Charlson comorbidity index; TACE: Transarterial chemoembolization; cTACE: Conventional transarterial chemoembolization; DEB-TACE: Drug-eluting bead transarterial chemoembolization.